FR2621127B1
(fr)
*
|
1987-09-30 |
1992-01-31 |
Roussy Inst Gustave |
Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
|
DE3828582A1
(de)
*
|
1988-08-23 |
1990-03-01 |
Max Planck Gesellschaft |
Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
|
US5766947A
(en)
*
|
1988-12-14 |
1998-06-16 |
Astra Ab |
Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
|
US5223426A
(en)
|
1988-12-15 |
1993-06-29 |
T Cell Sciences, Inc. |
Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
|
US6113903A
(en)
*
|
1989-03-21 |
2000-09-05 |
The Immune Response Corporation |
Peptides and methods against diabetes
|
US6207645B1
(en)
*
|
1989-03-21 |
2001-03-27 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
US6221352B1
(en)
|
1989-03-21 |
2001-04-24 |
The Immune Response Corporation |
Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
|
US5837246A
(en)
*
|
1989-03-21 |
1998-11-17 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
RU2138512C1
(ru)
*
|
1989-03-21 |
1999-09-27 |
Дзе Иммюн Риспонз Корпорейшн |
Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
|
AU652540B2
(en)
*
|
1989-07-19 |
1994-09-01 |
Xoma Corporation |
T cell receptor peptides as therapeutics for autoimmune and malignant disease
|
US5614192A
(en)
*
|
1989-07-19 |
1997-03-25 |
Connective Therapeutics, Inc. |
T cell receptor peptides as therapeutics for immune-related disease
|
US5776459A
(en)
*
|
1989-07-19 |
1998-07-07 |
Connetics Corporation |
TCR V beta 5 peptides
|
US5547669A
(en)
*
|
1989-11-03 |
1996-08-20 |
Immulogic Pharma Corp |
Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
|
WO1991007508A1
(en)
*
|
1989-11-15 |
1991-05-30 |
National Jewish Center For Immunology And Respiratory Medicine |
Method for measuring t-cell surface antigens in humans
|
EP0527199B2
(en)
*
|
1990-05-01 |
2000-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions for use in a method for treating a human suffering from multiple sclerosis
|
CA2065658A1
(en)
*
|
1991-04-19 |
1992-10-20 |
Tse-Wen Chang |
Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
|
CA2116526A1
(en)
*
|
1991-08-28 |
1993-03-18 |
William V. Williams |
T cell receptor-based therapy for rheumatoid arthritis
|
US5445940A
(en)
*
|
1991-08-28 |
1995-08-29 |
Brigham & Women's Hospital |
Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
|
US5747036A
(en)
*
|
1991-08-28 |
1998-05-05 |
Brigham & Women's Hospital |
Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
CA2144044A1
(en)
*
|
1992-09-14 |
1994-03-31 |
The Brigham And Women's Hospital |
Reagents and methods for treating rheumatoid arthritis
|
DE60024436T2
(de)
|
1999-05-07 |
2006-08-17 |
Genentech, Inc., South San Francisco |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
IL157145A0
(en)
|
2001-01-31 |
2004-02-08 |
Idec Pharma Corp |
Use of dc23 antagonists for the treatment of neoplastic disorders
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
RS51318B
(sr)
|
2002-12-16 |
2010-12-31 |
Genentech Inc. |
Varijante imunoglobulina i njihova upotreba
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
CN106075435A
(zh)
|
2004-06-04 |
2016-11-09 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
MX2007010922A
(es)
|
2005-03-10 |
2007-10-12 |
Genentech Inc |
Metodos y composiciones para modular la integridad vascular.
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
SI2083856T1
(sl)
|
2007-08-15 |
2011-02-28 |
Circassia Ltd |
Peptidi za desenzibilizacijo proti alergijam
|
EP3025714B9
(en)
|
2007-09-14 |
2020-11-18 |
Biogen MA Inc. |
Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
BRPI0908665A2
(pt)
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
AU2009303304A1
(en)
|
2008-10-10 |
2010-04-15 |
Anaphore, Inc. |
Polypeptides that bind TRAIL-RI and TRAIL-R2
|
ES2719496T3
(es)
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
AU2010297344A1
(en)
|
2009-09-17 |
2012-02-23 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
WO2012064627A2
(en)
|
2010-11-08 |
2012-05-18 |
Genentech, Inc. |
Subcutaneously administered anti-il-6 receptor antibody
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
CN109734807A
(zh)
|
2011-03-31 |
2019-05-10 |
豪夫迈·罗氏有限公司 |
施用β7整联蛋白拮抗剂的方法
|
EP3653218A1
(en)
|
2011-07-04 |
2020-05-20 |
Mesoblast, Inc. |
Methods of treating or preventing rheumatic disease
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
JP2014525412A
(ja)
|
2011-08-17 |
2014-09-29 |
ジェネンテック, インコーポレイテッド |
難治性腫瘍における血管新生の阻害
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
AR091305A1
(es)
|
2012-01-31 |
2015-01-28 |
Genentech Inc |
ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
WO2013123432A2
(en)
|
2012-02-16 |
2013-08-22 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
SG11201502548YA
(en)
|
2012-10-05 |
2015-04-29 |
Genentech Inc |
Methods for diagnosing and treating inflammatory bowel disease
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
WO2014151517A1
(en)
|
2013-03-15 |
2014-09-25 |
Intermune, Inc. |
Methods of improving microvascular integrity
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
MX2016012282A
(es)
|
2014-03-27 |
2017-01-06 |
Genentech Inc |
Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
|
EP3140392B1
(en)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Production of heteromultimeric proteins using mammalian cells
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
AR102918A1
(es)
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
PE20221008A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
PE20181004A1
(es)
|
2015-10-02 |
2018-06-26 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
EP3359572A2
(en)
|
2015-10-06 |
2018-08-15 |
H. Hoffnabb-La Roche Ag |
Method for treating multiple sclerosis
|
SG11201804961UA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Formulations with reduced degradation of polysorbate
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
WO2018106959A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
AU2017378406A1
(en)
|
2016-12-14 |
2019-06-13 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
CA3046019A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
US11033490B2
(en)
|
2016-12-14 |
2021-06-15 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
|
AU2017378393B2
(en)
|
2016-12-14 |
2023-03-09 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
|
EP3554541B1
(en)
|
2016-12-14 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
CN110072551B
(zh)
|
2016-12-14 |
2023-05-23 |
比奥拉治疗股份有限公司 |
使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
EP3600414A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
US20200094031A1
(en)
|
2017-03-30 |
2020-03-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
CN111601597B
(zh)
|
2017-08-23 |
2023-10-13 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
KR20210095165A
(ko)
|
2018-11-19 |
2021-07-30 |
프로제너티, 인크. |
바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
|
WO2020104705A2
(en)
|
2018-11-23 |
2020-05-28 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
EP4309722A2
(en)
|
2019-12-13 |
2024-01-24 |
Biora Therapeutics, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
WO2023086910A1
(en)
|
2021-11-12 |
2023-05-19 |
Genentech, Inc. |
Methods of treating crohn's disease using integrin beta7 antagonists
|